Collaboration with companies
Innovation and knowledge transfer
Cima is committed to being at the forefront of biomedical research in an environment of open innovation.
We promote collaboration with companies for the promotion of research and technology transfer. To this end, collaboration agreements have been established with other universities, technology centers, companies, foundations and national and international entities.
The starting point for research into new drugs is to understand the real needs of patients and to understand the mechanisms of the disease.
Need more information?
If you are interested in collaborating with us, please contact our Translation and Innovation Unit.
How does Cima collaborate with companies?
Once the "target" has been identified, the objective is to validate it in vivo. Thus, using different molecular tools, Cima scientists test the corresponding biological effect: both from an efficacy and safety point of view.
After validating the target, Cima develops molecules that interact with the therapeutic target and measures their functionality. They are then patented and offered to pharmaceutical companies for further development.
This stage includes the tests necessary to ensure that the drug is safe when administered to humans. In addition, it must also provide data suggesting that the potential drug has a potential effect.
Pharmaceutical companies evaluate whether a new drug is safe for use in humans and effective in patients presenting with the disease, as well as the effect of different doses. Many clinical trials are conducted at the Clínica Universidad de Navarra.
Research and development of a drug
The starting point for research into new drugs is to understand the real needs of patients and to understand the mechanisms of that disease.
At Cima, this discovery phase is carried out and, with the help of pharmaceutical companies and companies, further development is achieved until the drug is made available to patients.